Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Vamorolone trial in Duchenne muscular dystrophy shows dose-related improvement of muscle function.

Hoffman EP, Schwartz BD, Mengle-Gaw LJ, Smith EC, Castro D, Mah JK, McDonald CM, Kuntz NL, Finkel RS, Guglieri M, Bushby K, Tulinius M, Nevo Y, Ryan MM, Webster R, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Siener C, Jaros M, Shale P, McCall JM, Nagaraju K, van den Anker J, Conklin LS, Cnaan A, Gordish-Dressman H, Damsker JM, Clemens PR; and the Cooperative International Neuromuscular Research Group.

Neurology. 2019 Aug 26. pii: 10.1212/WNL.0000000000008168. doi: 10.1212/WNL.0000000000008168. [Epub ahead of print]

PMID:
31451516
2.

Vamorolone, a dissociative steroidal compound, reduces collagen antibody-induced joint damage and inflammation when administered after disease onset.

Damsker JM, Cornish MR, Kanneboyina P, Kanneboyina I, Yu Q, Lipson R, Phadke A, Knoblach SM, Panchapakesan K, Morales M, Fiorillo AA, Partridge T, Nagaraju K.

Inflamm Res. 2019 Aug 24. doi: 10.1007/s00011-019-01279-z. [Epub ahead of print]

PMID:
31446438
3.

Orthogonal analysis of dystrophin protein and mRNA as a surrogate outcome for drug development.

Uaesoontrachoon K, Srinivassane S, Warford J, Mekhssian K, Montpetit H, Beauvois R, Keyhani A, Hathout Y, Yamashita T, Satou Y, Osaki H, Praest M, Moraca M, Malbasic M, Ross W, MacKinnon A, Rowsell J, Mullen A, Matyas M, Mummidivarpu S, Nagaraju K, Hoffman EP.

Biomark Med. 2019 Aug 5. doi: 10.2217/bmm-2019-0242. [Epub ahead of print]

4.

Discovery of potential urine-accessible metabolite biomarkers associated with muscle disease and corticosteroid response in the mdx mouse model for Duchenne.

Thangarajh M, Zhang A, Gill K, Ressom HW, Li Z, Varghese RS, Hoffman EP, Nagaraju K, Hathout Y, Boca SM.

PLoS One. 2019 Jul 16;14(7):e0219507. doi: 10.1371/journal.pone.0219507. eCollection 2019.

5.

AMP-activated protein kinase signaling regulated expression of urea cycle enzymes in response to changes in dietary protein intake.

Heibel SK, McGuire PJ, Haskins N, Majumdar HD, Rayavarapu S, Nagaraju K, Hathout Y, Brown K, Tuchman M, Caldovic L.

J Inherit Metab Dis. 2019 Jun 8. doi: 10.1002/jimd.12133. [Epub ahead of print]

PMID:
31177541
6.

A cellular automaton model to find the risk of developing autism through gut-mediated effects.

Nagaraju K, Sudeep KS, Kurhekar MP.

Comput Biol Med. 2019 Jul;110:207-217. doi: 10.1016/j.compbiomed.2019.05.015. Epub 2019 May 25.

PMID:
31173944
7.

Fibroadipogenic progenitors are responsible for muscle loss in limb girdle muscular dystrophy 2B.

Hogarth MW, Defour A, Lazarski C, Gallardo E, Diaz Manera J, Partridge TA, Nagaraju K, Jaiswal JK.

Nat Commun. 2019 Jun 3;10(1):2430. doi: 10.1038/s41467-019-10438-z.

8.

Mitochondrial dysfunction and role of harakiri in the pathogenesis of myositis.

Boehler JF, Horn A, Novak JS, Li N, Ghimbovschi S, Lundberg IE, Alexanderson H, Alemo Munters L, Jaiswal JK, Nagaraju K.

J Pathol. 2019 May 28. doi: 10.1002/path.5309. [Epub ahead of print]

PMID:
31135059
9.

Morpholino-induced exon skipping stimulates cell-mediated and humoral responses to dystrophin in mdx mice.

Vila MC, Novak JS, Benny Klimek M, Li N, Morales M, Fritz AG, Edwards K, Boehler JF, Hogarth MW, Kinder TB, Zhang A, Mazala D, Fiorillo AA, Douglas B, Chen YW, van den Anker J, Lu QL, Hathout Y, Hoffman EP, Partridge TA, Nagaraju K.

J Pathol. 2019 Jul;248(3):339-351. doi: 10.1002/path.5263. Epub 2019 Apr 16.

PMID:
30883742
10.

Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy.

Heier CR, Yu Q, Fiorillo AA, Tully CB, Tucker A, Mazala DA, Uaesoontrachoon K, Srinivassane S, Damsker JM, Hoffman EP, Nagaraju K, Spurney CF.

Life Sci Alliance. 2019 Feb 11;2(1). pii: e201800186. doi: 10.26508/lsa.201800186. Print 2019 Feb.

11.

Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy.

Mavroudis PD, van den Anker J, Conklin LS, Damsker JM, Hoffman EP, Nagaraju K, Clemens PR, Jusko WJ.

J Clin Pharmacol. 2019 Jul;59(7):979-988. doi: 10.1002/jcph.1388. Epub 2019 Feb 11.

PMID:
30742306
12.

Radiological analysis of the sella turcica and its correlations with body mass index in a North Indian population.

Gargi V, Ravi Prakash SM, Nagaraju K, Malik S, Goel S, Gupta S.

Oral Radiol. 2019 May;35(2):184-188. doi: 10.1007/s11282-018-0337-9. Epub 2018 Jun 19.

PMID:
30484194
13.

Serum biomarkers of glucocorticoid response and safety in anti-neutrophil cytoplasmic antibody-associated vasculitis and juvenile dermatomyositis.

Conklin LS, Merkel PA, Pachman LM, Parikh H, Tawalbeh S, Damsker JM, Cuthbertson DD, Morgan GA, Monach PA, Hathout Y, Nagaraju K, van den Anker J, McAlear CA, Hoffman EP.

Steroids. 2018 Dec;140:159-166. doi: 10.1016/j.steroids.2018.10.008. Epub 2018 Oct 21.

14.

Oxidative coupling strategies for the synthesis of indole alkaloids.

Nagaraju K, Ma D.

Chem Soc Rev. 2018 Oct 29;47(21):8018-8029. doi: 10.1039/c8cs00305j. Review.

PMID:
30221274
15.

Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-inflammatory drug.

Conklin LS, Damsker JM, Hoffman EP, Jusko WJ, Mavroudis PD, Schwartz BD, Mengle-Gaw LJ, Smith EC, Mah JK, Guglieri M, Nevo Y, Kuntz N, McDonald CM, Tulinius M, Ryan MM, Webster R, Castro D, Finkel RS, Smith AL, Morgenroth LP, Arrieta A, Shimony M, Jaros M, Shale P, McCall JM, Hathout Y, Nagaraju K, van den Anker J, Ward LM, Ahmet A, Cornish MR, Clemens PR.

Pharmacol Res. 2018 Oct;136:140-150. doi: 10.1016/j.phrs.2018.09.007. Epub 2018 Sep 13.

16.

"Of Mice and Measures": A Project to Improve How We Advance Duchenne Muscular Dystrophy Therapies to the Clinic.

Gordish-Dressman H, Willmann R, Dalle Pazze L, Kreibich A, van Putten M, Heydemann A, Bogdanik L, Lutz C, Davies K, Demonbreun AR, Duan D, Elsey D, Fukada SI, Girgenrath M, Patrick Gonzalez J, Grounds MD, Nichols A, Partridge T, Passini M, Sanarica F, Schnell FJ, Wells DJ, Yokota T, Young CS, Zhong Z, Spurney C, Spencer M, De Luca A, Nagaraju K, Aartsma-Rus A.

J Neuromuscul Dis. 2018;5(4):407-417. doi: 10.3233/JND-180324.

17.

Membrane Stabilization by Modified Steroid Offers a Potential Therapy for Muscular Dystrophy Due to Dysferlin Deficit.

Sreetama SC, Chandra G, Van der Meulen JH, Ahmad MM, Suzuki P, Bhuvanendran S, Nagaraju K, Hoffman EP, Jaiswal JK.

Mol Ther. 2018 Sep 5;26(9):2231-2242. doi: 10.1016/j.ymthe.2018.07.021. Epub 2018 Aug 27.

18.

The role of nitrite in muscle function, susceptibility to contraction injury, and fatigability in sickle cell mice.

Wang L, Almeida LEF, Kamimura S, van der Meulen JH, Nagaraju K, Quezado M, Wakim P, Quezado ZMN.

Nitric Oxide. 2018 Nov 1;80:70-81. doi: 10.1016/j.niox.2018.08.005. Epub 2018 Aug 14.

PMID:
30114530
19.

Synthesis, Characterization, and Function of an RNA-Based Transfection Reagent.

Jain HV, Boehler JF, Nagaraju K, Beaucage SL.

Curr Protoc Nucleic Acid Chem. 2018 Mar;72(1):4.81.1-4.81.29. doi: 10.1002/cpnc.51.

20.

Muscle miRNAome shows suppression of chronic inflammatory miRNAs with both prednisone and vamorolone.

Fiorillo AA, Tully CB, Damsker JM, Nagaraju K, Hoffman EP, Heier CR.

Physiol Genomics. 2018 Sep 1;50(9):735-745. doi: 10.1152/physiolgenomics.00134.2017. Epub 2018 Jun 8.

21.

Organocatalytic synthesis of densely functionalized oxa-bridged 2,6-epoxybenzo[b][1,5]oxazocine heterocycles.

Gurubrahamam R, Nagaraju K, Chen K.

Chem Commun (Camb). 2018 Jun 8;54(47):6048-6051. doi: 10.1039/c8cc02565g.

PMID:
29799038
22.

Risk factors and disease mechanisms in myositis.

Miller FW, Lamb JA, Schmidt J, Nagaraju K.

Nat Rev Rheumatol. 2018 Apr 20;14(5):255-268. doi: 10.1038/nrrheum.2018.48. Review.

23.

Skeletal, cardiac, and respiratory muscle function and histopathology in the P448Lneo- mouse model of FKRP-deficient muscular dystrophy.

Yu Q, Morales M, Li N, Fritz AG, Ruobing R, Blaeser A, Francois E, Lu QL, Nagaraju K, Spurney CF.

Skelet Muscle. 2018 Apr 6;8(1):13. doi: 10.1186/s13395-018-0158-x.

24.

Design, synthesis, neuroprotective, antibacterial activities and docking studies of novel thieno[2,3-d]pyrimidine-alkyne Mannich base and oxadiazole hybrids.

Triloknadh S, Venkata Rao C, Nagaraju K, Hari Krishna N, Venkata Ramaiah C, Rajendra W, Trinath D, Suneetha Y.

Bioorg Med Chem Lett. 2018 May 15;28(9):1663-1669. doi: 10.1016/j.bmcl.2018.03.030. Epub 2018 Mar 13.

PMID:
29602681
25.

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2018 Mar 23;9(1):1256. doi: 10.1038/s41467-018-03709-8.

26.

Phase 1 trial of vamorolone, a first-in-class steroid, shows improvements in side effects via biomarkers bridged to clinical outcomes.

Hoffman EP, Riddle V, Siegler MA, Dickerson D, Backonja M, Kramer WG, Nagaraju K, Gordish-Dressman H, Damsker JM, McCall JM.

Steroids. 2018 Jun;134:43-52. doi: 10.1016/j.steroids.2018.02.010. Epub 2018 Mar 8.

27.

Update on Standard Operating Procedures in Preclinical Research for DMD and SMA Report of TREAT-NMD Alliance Workshop, Schiphol Airport, 26 April 2015, The Netherlands.

van Putten M, Aartsma-Rus A, Grounds MD, Kornegay JN, Mayhew A, Gillingwater TH, Takeda S, Rüegg MA, De Luca A, Nagaraju K, Willmann R.

J Neuromuscul Dis. 2018;5(1):29-34. doi: 10.3233/JND-170288.

28.

Author Correction: Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2018 Jan 15;9(1):208. doi: 10.1038/s41467-017-02206-8.

29.

Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.

Capogrosso RF, Mantuano P, Uaesoontrachoon K, Cozzoli A, Giustino A, Dow T, Srinivassane S, Filipovic M, Bell C, Vandermeulen J, Massari AM, De Bellis M, Conte E, Pierno S, Camerino GM, Liantonio A, Nagaraju K, De Luca A.

FASEB J. 2018 Feb;32(2):1025-1043. doi: 10.1096/fj.201700182RRR. Epub 2018 Jan 3.

30.

Myoblasts and macrophages are required for therapeutic morpholino antisense oligonucleotide delivery to dystrophic muscle.

Novak JS, Hogarth MW, Boehler JF, Nearing M, Vila MC, Heredia R, Fiorillo AA, Zhang A, Hathout Y, Hoffman EP, Jaiswal JK, Nagaraju K, Cirak S, Partridge TA.

Nat Commun. 2017 Oct 16;8(1):941. doi: 10.1038/s41467-017-00924-7. Erratum in: Nat Commun. 2018 Jan 15;9(1):208. Nat Commun. 2018 Mar 23;9(1):1256.

31.

An amphipathic trans-acting phosphorothioate RNA element delivers an uncharged phosphorodiamidate morpholino sequence in mdx mouse myotubes.

Jain HV, Boehler JF, Verthelyi D, Nagaraju K, Beaucage SL.

RSC Adv. 2017;7:42519-42528. doi: 10.1039/C7RA04247G. Epub 2017 Sep 4.

32.

Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.

Echigoya Y, Lim KRQ, Trieu N, Bao B, Miskew Nichols B, Vila MC, Novak JS, Hara Y, Lee J, Touznik A, Mamchaoui K, Aoki Y, Takeda S, Nagaraju K, Mouly V, Maruyama R, Duddy W, Yokota T.

Mol Ther. 2017 Nov 1;25(11):2561-2572. doi: 10.1016/j.ymthe.2017.07.014. Epub 2017 Jul 28.

33.

Effect of endurance exercise on microRNAs in myositis skeletal muscle-A randomized controlled study.

Boehler JF, Hogarth MW, Barberio MD, Novak JS, Ghimbovschi S, Brown KJ, Alemo Munters L, Loell I, Chen YW, Gordish-Dressman H, Alexanderson H, Lundberg IE, Nagaraju K.

PLoS One. 2017 Aug 22;12(8):e0183292. doi: 10.1371/journal.pone.0183292. eCollection 2017.

34.

Improving Reproducibility of Phenotypic Assessments in the DyW Mouse Model of Laminin-α2 Related Congenital Muscular Dystrophy.

Willmann R, Gordish-Dressman H, Meinen S, Rüegg MA, Yu Q, Nagaraju K, Kumar A, Girgenrath M, Coffey CBM, Cruz V, Van Ry PM, Bogdanik L, Lutz C, Rutkowski A, Burkin DJ.

J Neuromuscul Dis. 2017;4(2):115-126. doi: 10.3233/JND-170217. Review.

35.

Coexistence of hard palate carcinoma with tuberculosis: A rarity.

Verma SK, Srivastava A, Nagaraju K, Mishra AK, Goel MM.

J Cancer Res Ther. 2017 Jan-Mar;13(1):142-144. doi: 10.4103/0973-1482.174538.

36.

Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle.

Defour A, Medikayala S, Van der Meulen JH, Hogarth MW, Holdreith N, Malatras A, Duddy W, Boehler J, Nagaraju K, Jaiswal JK.

Hum Mol Genet. 2017 Jun 1;26(11):1979-1991. doi: 10.1093/hmg/ddx065.

37.

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy.

Vila MC, Rayavarapu S, Hogarth MW, Van der Meulen JH, Horn A, Defour A, Takeda S, Brown KJ, Hathout Y, Nagaraju K, Jaiswal JK.

Cell Death Differ. 2017 Feb;24(2):330-342. doi: 10.1038/cdd.2016.127. Epub 2016 Nov 11.

38.

Serum pharmacodynamic biomarkers for chronic corticosteroid treatment of children.

Hathout Y, Conklin LS, Seol H, Gordish-Dressman H, Brown KJ, Morgenroth LP, Nagaraju K, Heier CR, Damsker JM, van den Anker JN, Henricson E, Clemens PR, Mah JK, McDonald C, Hoffman EP.

Sci Rep. 2016 Aug 17;6:31727. doi: 10.1038/srep31727.

39.

OPN-a induces muscle inflammation by increasing recruitment and activation of pro-inflammatory macrophages.

Many GM, Yokosaki Y, Uaesoontrachoon K, Nghiem PP, Bello L, Dadgar S, Yin Y, Damsker JM, Cohen HB, Kornegay JN, Bamman MM, Mosser DM, Nagaraju K, Hoffman EP.

Exp Physiol. 2016 Oct 1;101(10):1285-1300. doi: 10.1113/EP085768. Epub 2016 Sep 24.

40.

Patients' perceptions about the implementation of Revised National Tuberculosis Control Programme of India.

Verma SK, Nagaraju K, Kant S, Kushwaha RA, Kumar S, Garg R.

Indian J Tuberc. 2016 Apr;63(2):86-90. doi: 10.1016/j.ijtb.2015.06.002. Epub 2016 Jun 4.

PMID:
27451816
41.

Effects on muscle tissue remodeling and lipid metabolism in muscle tissue from adult patients with polymyositis or dermatomyositis treated with immunosuppressive agents.

Loell I, Raouf J, Chen YW, Shi R, Nennesmo I, Alexanderson H, Dastmalchi M, Nagaraju K, Korotkova M, Lundberg IE.

Arthritis Res Ther. 2016 Jun 10;18(1):136. doi: 10.1186/s13075-016-1033-y.

42.

Muscle myeloid type I interferon gene expression may predict therapeutic responses to rituximab in myositis patients.

Nagaraju K, Ghimbovschi S, Rayavarapu S, Phadke A, Rider LG, Hoffman EP, Miller FW.

Rheumatology (Oxford). 2016 Sep;55(9):1673-80. doi: 10.1093/rheumatology/kew213. Epub 2016 May 23.

43.

Effect of the IL-1 Receptor Antagonist Kineret® on Disease Phenotype in mdx Mice.

Benny Klimek ME, Sali A, Rayavarapu S, Van der Meulen JH, Nagaraju K.

PLoS One. 2016 May 23;11(5):e0155944. doi: 10.1371/journal.pone.0155944. eCollection 2016.

44.

Expanding Diversity without Protecting Groups: (+)-Sclareolide to Indolosesquiterpene Alkaloid Mycoleptodiscin A and Analogues.

Nagaraju K, Chegondi R, Chandrasekhar S.

Org Lett. 2016 Jun 3;18(11):2684-7. doi: 10.1021/acs.orglett.6b01145. Epub 2016 May 16.

PMID:
27181938
45.

Airway Diseases Education and Expertise (ADEX ) in Pediatrics: Adaptation for Clinical Practice in India.

Paramesh H, Nagaraju K, Sukumaran TU, Agarkhedkar S, Bhakta S, Tilak R, Vijayasekaran D, Narayanan V, Mane A, Phansalkar A, Kadhe G.

Indian Pediatr. 2016 Feb;53(2):154-8.

PMID:
26897152
46.

Endurance Exercise Improves Molecular Pathways of Aerobic Metabolism in Patients With Myositis.

Munters LA, Loell I, Ossipova E, Raouf J, Dastmalchi M, Lindroos E, Chen YW, Esbjörnsson M, Korotkova M, Alexanderson H, Nagaraju K, Crofford LJ, Jakobsson PJ, Lundberg IE.

Arthritis Rheumatol. 2016 Jul;68(7):1738-50. doi: 10.1002/art.39624.

47.

Design, architecture and application of nanorobotics in oncology.

Saxena S, Pramod BJ, Dayananda BC, Nagaraju K.

Indian J Cancer. 2015 Apr-Jun;52(2):236-41. doi: 10.4103/0019-509X.175805. Review.

48.

The use of proteomic analysis to study trafficking defects in axons.

Fu X, Brown KJ, Rayavarapu S, Nagaraju K, Liu JS.

Methods Cell Biol. 2016;131:151-62. doi: 10.1016/bs.mcb.2015.06.009. Epub 2015 Sep 2.

PMID:
26794512
49.

Annexin A1 Deficiency does not Affect Myofiber Repair but Delays Regeneration of Injured Muscles.

Leikina E, Defour A, Melikov K, Van der Meulen JH, Nagaraju K, Bhuvanendran S, Gebert C, Pfeifer K, Chernomordik LV, Jaiswal JK.

Sci Rep. 2015 Dec 15;5:18246. doi: 10.1038/srep18246.

50.

A review on protein functionalized carbon nanotubes.

Nagaraju K, Reddy R, Reddy N.

J Appl Biomater Funct Mater. 2015 Dec 18;13(4):e301-12. doi: 10.5301/jabfm.5000231. Review.

PMID:
26660626

Supplemental Content

Loading ...
Support Center